Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

RBC Capital analyst Jon Arfstrom raised the firm’s price target on Bread Financial (BFH) to $68 from $62 and keeps a Sector Perform rating on ...

We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look at where Merck KGaA (OTC:MKGAF) stands against Morgan Stanley’s other ...

The Real Good Food Company (RGF) announced on Thursday its intention to voluntarily delist its common stock from the Nasdaq ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Decided to add this retail giant to your portfolio? Here's what you need to know before buying Amazon stock. Many, or all, of the products featured on this page are from our advertising partners ...

There are 10 companies in the world that currently have a market cap of more than $1 trillion. It would be reasonable to assume that none of these businesses have bargain stocks. These companies ...

The key, of course, is to know which growth stocks to buy and when. Some growth stocks fell much more, with stock prices cut by half or two-thirds. But growth stocks rebounded in 2023, outpacing ...

The Magnificent Seven have been under pressure recently because of criticism their stock prices may have shot too high after leading the market for so many years. Such worries grew after Treasury ...

while trimming our Sep-25E target price by 6 per cent to Rs 1,570 due to 10% cut in Retail multiple. New energy development and vertical monetization are key triggers for the stock," it said.

A price hike is coming for folks with five or more lines on current plans and those still holding on to venerable plans no longer offered. David Lumb is a mobile reporter covering how on-the-go ...

Netflix Inc.’s stock was flat Friday after Benchmark analysts reiterated their sell rating on the stock even as they raised their price target by 30%, arguing that it’s looking overvalued in a ...